Compare KEQU & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEQU | SENS |
|---|---|---|
| Founded | 1906 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Industrial Machinery/Components |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.5M | 301.2M |
| IPO Year | 1995 | 2014 |
| Metric | KEQU | SENS |
|---|---|---|
| Price | $36.20 | $7.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.38 |
| AVG Volume (30 Days) | 3.2K | ★ 586.9K |
| Earning Date | 03-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.22 | N/A |
| Revenue | ★ $138,558,000.00 | $16,389,000.00 |
| Revenue This Year | N/A | $74.15 |
| Revenue Next Year | N/A | $58.60 |
| P/E Ratio | $11.30 | ★ N/A |
| Revenue Growth | 7.72 | ★ 19.85 |
| 52 Week Low | $33.27 | $0.41 |
| 52 Week High | $60.89 | $8.75 |
| Indicator | KEQU | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 51.51 | 79.45 |
| Support Level | $35.21 | $7.35 |
| Resistance Level | $38.57 | $8.49 |
| Average True Range (ATR) | 0.89 | 0.39 |
| MACD | 0.07 | 0.35 |
| Stochastic Oscillator | 69.45 | 95.27 |
Kewaunee Scientific Corp is engaged in the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. Its products include steel and wood casework, fume hoods, adaptable modular systems, movable workstations, stand-alone benches, biological safety cabinets, epoxy resin work surfaces, and sinks. The company operates through two reportable segments: Lab Products Group (LPG), which designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, flexible systems, work surfaces, workstations, workbenches, and computer enclosures, and the International segment.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.